Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

TitleAnimal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.
Publication TypeJournal Article
Year of Publication2013
AuthorsIttmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A, Cardiff RD
JournalCancer Res
Volume73
Issue9
Pagination2718-36
Date Published2013 May 01
ISSN1538-7445
KeywordsAdenocarcinoma, Animals, Consensus, Disease Models, Animal, Disease Progression, Gene Expression Regulation, Neoplastic, Genetic Engineering, Humans, Male, Mice, Neoplasm Metastasis, Neoplasm Transplantation, New York, Oncogenes, Prostatic Neoplasms, Rats, Societies, Medical
Abstract

Animal models, particularly mouse models, play a central role in the study of the etiology, prevention, and treatment of human prostate cancer. While tissue culture models are extremely useful in understanding the biology of prostate cancer, they cannot recapitulate the complex cellular interactions within the tumor microenvironment that play a key role in cancer initiation and progression. The National Cancer Institute (NCI) Mouse Models of Human Cancers Consortium convened a group of human and veterinary pathologists to review the current animal models of prostate cancer and make recommendations about the pathologic analysis of these models. More than 40 different models with 439 samples were reviewed, including genetically engineered mouse models, xenograft, rat, and canine models. Numerous relevant models have been developed over the past 15 years, and each approach has strengths and weaknesses. Analysis of multiple genetically engineered models has shown that reactive stroma formation is present in all the models developing invasive carcinomas. In addition, numerous models with multiple genetic alterations display aggressive phenotypes characterized by sarcomatoid carcinomas and metastases, which is presumably a histologic manifestation of epithelial-mesenchymal transition. The significant progress in development of improved models of prostate cancer has already accelerated our understanding of the complex biology of prostate cancer and promises to enhance development of new approaches to prevention, detection, and treatment of this common malignancy.

DOI10.1158/0008-5472.CAN-12-4213
Alternate JournalCancer Res
PubMed ID23610450
Grant ListP30CA125123 / CA / NCI NIH HHS / United States
P01 CA89021 / CA / NCI NIH HHS / United States
P30 CA069533 13S5 / CA / NCI NIH HHS / United States
U01CA141497 / CA / NCI NIH HHS / United States
Related Faculty: 
Brian Robinson, M.D. Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700